Free Webinar | Multiplexing qPCR Assays for SARS-CoV-2 Variants and Beyond

September 14, 2021 | 11:00 am – 12:00 pm EDT

What Does It Cover?

The current pandemic has shown us that next-generation detection assays must be robust and flexible enough to recognize multiple strain variants. Multiplexing of qPCR assays allows for detection of multiple targets from a single sample offering savings in time, sample, and reaction components. Multiplexed assays require certain unique considerations for successful development. Our expert will provide insights into constructing and optimizing an effective multiplexed assay in the context of the COVID pandemic.

What Will You Learn?

  • Multiplex vs. Singleplex Assay Design
  • Component Optimization
  • Multiplexed Covid Variant Detection

Who Should Attend?

  • Diagnostic Test Developers
  • Testing Laboratory Personnel
  • Clinical Testing End Users

Speaker Biography

Vikas Palhan, PhD
Senior R&D Scientist, Diagnostic Solutions, MilliporeSigma

Vikas Palhan, PhD, is a senior scientist in the Molecular Diagnostics group at MilliporeSigma in St. Louis, MO, USA. He joined MilliporeSigma in 2007 and over the last 14 years has developed ChIP, RIP and ChIRP kits for Genomics & Epigenetics research. He is currently developing multiplex q-RT-PCR assays for detection of SARS-CoV-2 variants and wildtype virus that cause COVID-19.

Prior to MilliporeSigma, Vikas completed his postdoc at Rockefeller University, New York, in Bob Roeder’s lab working on transcription regulation at the chromatin level in human cell-free systems. Vikas completed his doctoral studies at the Indian Institute of Science in Bangalore, India, working on the biotechnological applications of the silkworm baculovirus. His research studies have led to several patents and publications.


MilliporeSigma logo